Description
This new indication adds to the prescribing label for Wegovy, a prescription-only medicine previously approved for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off when used along with a reduced calorie diet and increased physical activity.
“Today, we’re taking a pivotal step forward in addressing some of the most pressing health issues of our time with the added indication for Wegovy,” said Doug Langa, executive vice president, head of North America operations, and president of Novo Nordisk. “We recognise how important this moment is for the millions of people who live with excess weight or obesity and known heart disease, and we will continue to advance options that put their needs first. Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine.”
